“It was a dream of mine to give back to the school.”
The Harvey Co Chien Endowed Scholarship for Biostatistics was established to support students pursuing master's degrees in the Department of Biostatistics. Harvey Co Chien moved from the Philippines and obtained his MS in Biostatistics from Pitt Public Health in 1987. His generous gift has enabled recipients to access top-notch education, while developing character and teaching integrity in the field of biostatistics.
How it Began
Noting that international students are at a particular disadvantage by not being eligible for student loans— as well as recognizing the crucial role that funding played in finishing his own degree — Chien wanted to provide a solution. It was then that he decided to create the department’s first endowed scholarship to invest in recruiting and educating the very best students.
Support the Co Chien Scholarship
Please enter Co Chien Scholarship in the other box when prompted on Page 2 of Pitt Giving.
- About Harvey Co Chien
-
Harvey Co Chien moved from the Philippines and obtained his MS in Biostatistics from Pitt Public Health in 1987. His Masters’ thesis was on developing an analytic module for OCMAP (Occupational Cohort Mortality Analysis Program). In 1989, a paper on this module was published in the American Statistician, and later the Software won an Innovator Award at the University's 14th Annual Celebration of Innovation.
After his graduation from Pitt Public Health, Harvey Co Chien spent nearly a decade with Westat, Inc., working on biostatistics and epidemiology projects and studying cancer risk factors. Later, he collaborated with Alza Corporation (a Johnson and Johnson Company) on drug delivery technology for children with ADHD, after which he became an associate director at InterMune. In 2007, he founded his own biostatistics consulting company, Synerstat.
Harvey’s research interests include CNS, inflammation/pain/abuse liability, cancer risk factors, urology, hepatology, and pulmonology. His expertise also encompasses controlled and observational studies, clinical trials, and the development of computer software. He is currently retired and resides in San Francisco, California.